Business Wire

UAE's Technology Innovation Institute Launches Open-Source "Falcon 40B" Large Language Model for Research & Commercial Utilization

25.5.2023 12:47:00 EEST | Business Wire | Press release

Share

The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today strengthened its growing international influence in the field of artificial intelligence by announcing that "Falcon 40B," the UAE's first large-scale AI model, is now open source for research and commercial use. This pioneering move demonstrates Abu Dhabi's commitment to fostering collaboration across sectors and driving advancements in generative AI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005043/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

"Falcon 40B," the UAE's first large-scale AI model, is now open source for research and commercial use. (Photo: AETOSWire)

Falcon, a foundational large language model (LLM) with 40 billion parameters, trained on one trillion tokens, grants unprecedented access to researchers and small and medium-sized enterprise (SME) innovators alike. TII is providing access to the model’s weights as a more comprehensive open-source package, with the aim of enabling access to powerful LLM capabilities, promoting transparency and accountability, and supporting innovation and research in the field.

In the current AI ecosystem, developers are finding LLMs that provide access to model weights more appealing due to the enhanced capabilities they offer for fine-tuning compared to those without. While the majority of LLMs have granted exclusive licenses solely to non-commercial users, TII has taken a key stride in offering researchers and commercial users access to the Falcon 40B LLM.

In conjunction with the release of Falcon 40B as an open-source model, TII has launched a call for proposals, inviting scientists, researchers, and visionaries who are enthusiastic about harnessing the potential of the foundation model. They are encouraged to contribute their innovative ideas and leverage the model to build inspiring use cases or explore further possibilities for its application to cover areas like engineering, healthcare, sustainability, coding, and much more.

As an incentive for exceptional research proposals, selected projects will receive “training compute power” in the form of investment, enabling innovators to leverage robust computational resources for accelerated data analysis, complex modeling, and new discoveries. This support will nurture and accelerate the development of novel ideas, providing the necessary resources to turn them into impactful AI solutions with commercial viability and societal benefits.

VentureOne, the commercialization arm of ATRC, will facilitate computation power to productize the most innovative solutions.

"Making Falcon 40B open source represents a critical milestone in our commitment to fostering AI innovation," said H.E.Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC). "We are disrupting LLM access and enabling researchers and entrepreneurs to come up with the most innovative use cases. We will further support these submissions with computation power as funding through VentureOne, helping to advance a thriving research ecosystem.”

Falcon, first unveiled in March 2023, showcased exceptional performance and underscored the UAE's commitment to technological progress. Based on Stanford University’s HELM LLM benchmarking tool, Falcon 40B outperformed its renowned counterparts in utilizing significantly less training compute power. With only 75 percent of the training compute of OpenAI's GPT-3, 40 percent of DeepMind's Chinchilla AI, and 80 percent of the training compute of Google's PaLM-62B, the tool substantiated TII's commitment to advancing developments in generative AI.

Dr. Ray O. Johnson, CEO of TII, said: "Computing power plays a pivotal role in expediting AI system training and enabling faster implementation of use cases. As the new fuel that drives technological innovation, the move to offer such support will be game-changing in enhancing the capabilities of innovators, and enabling them to push the boundaries of their projects to achieve remarkable advancements."

Falcon 40B is a breakthrough led by TII’s AI and Digital Science Research Center (AIDRC). The same team also launched NOOR, the world’s largest Arabic NLP model last year, and is on track to develop and announce Falcon 180B soon.

Dr. Ebtesam Almazrouei Director, AI Cross-Center Unit, TII, said: “The open-source release of Falcon 40B, 7.5B, and 1.3B parameter AI models and our high-quality REFINEDWEB dataset, exemplifies the profound scientific contributions of the UAE. With each breakthrough, we defy limitations, reshape the realm of possibilities, and pave the way for collaborative efforts with transformative impact."

The UAE recently moved up five places to rank as the top Arab country and the 37th out of 166 countries in the UN Frontier Technologies Readiness Index 2023. Complementing a long list of progressive technology milestones, the open-source generative AI model is set to boost the UAE’s credentials as a mainstream AI player.

If you are interested in accessing the Falcon AI models or submitting for the use case call for proposal, we invite you to visit FalconLLM.TII.ae. Falcon LLMs open sourced to date, will be made available under a license built upon the principles of open-source Apache 2.0 software, which allows for a wide range of free use.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye